SARS-CoV-2 Nucleoprotein (126-140)
NKDGIIWVATEGALN is a SARS-CoV-2 nucleoprotein (126-140) epitope. It is an epitope suitable for anti-viral targeting.
Catalogue number crb1001762 Molecular Weight 1599.8 Sequence (one letter code)
Sequence (three letter code)
Purity >95% Storage -20°C References
Gupta et al., (2006). SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens. Virology, 347(1): 127.
Zhuang et al., (2021). Mapping and role of T cell response in SARS-CoV-2–infected mice. JEM, 218(4). DOI: 10.1084/jem.20202187.
Manufactured in: United Kingdom
The coronavirus (CoV) nucleoprotein is the major component of CoV structural proteins. Also known as the nucleocapsid protein, it is an abundant RNA-binding protein critical for viral genome packaging. These factors make nucleoprotein a good target for developing new antiviral drugs. In addition, the identification of epitopes within the nucleoprotein sequence can help design more effective SARS-CoV-2 vaccines.
Models have predicted epitopes exhibiting antigenicity, stability and interactions with MHC class-I and class-II molecules. Nucleoprotein (56-70) is an epitope candidate with various HLA restrictions. This epitope can be used to better vaccine design for more durable CD4+ and CD8+ T cell responses for long-lasting immunity.